Effects of Perioperative Intravenous Dexamethasone on Pain in Out Patient Knee Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01149616 |
Recruitment Status :
Terminated
(investigators changed jobs, no longer affiliated with institution)
First Posted : June 23, 2010
Results First Posted : July 7, 2017
Last Update Posted : July 7, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Post Operative Pain Nausea | Drug: Dexamethasone 8mg iv x1 Drug: placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 82 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effects of Perioperative Intravenous Dexamethasone on Pain in Out Patient Knee Surgery |
Study Start Date : | December 2009 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | December 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Intervention
Dexamethasone 8mg iv x 1
|
Drug: Dexamethasone 8mg iv x1
Dexamethasone 8mg iv x1 |
Placebo Comparator: Placebo
placebo
|
Drug: placebo
2 ml normal saline IV x1 |
- Post Operative VAS Pain Scale [ Time Frame: 24 hours ]Patients were instructed to select a number between zero and ten to indicate the degree of pain they experience (zero being no pain and ten being the worst pain they could imagine). Therefore, ten is worse than zero.
- Amount of Postop Narcotic Usage [ Time Frame: 24 hours ]Patients were requested to record the number of prescribed oral analgesic (oxycodone 5 mg/aceteminophen 325 mg) tablets taken for the first 24 hours following discharge
- Postop Nausea [ Time Frame: 24 hours ]NRS scale 0-10 for nausea. Zero indicates no nausea, Ten indicates the worst nausea imagined.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Adult patients undergoing ambulatory knee arthroscopy surgery
- Must provide phone contact number and agree to phone followup on post operative day 1
Exclusion Criteria:
- Patients with major systemic disease
- Allergy or intolerance to study drug

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01149616
United States, Massachusetts | |
Beth Israel Deaconess Medical Center | |
Boston, Massachusetts, United States, 02215 |
Principal Investigator: | Lauren Fisher, DO | Beth Israel Deaconess Medical Center |
Responsible Party: | Lauren J. Fisher, Attending Physician, Beth Israel Deaconess Medical Center |
ClinicalTrials.gov Identifier: | NCT01149616 |
Other Study ID Numbers: |
2009P000345 |
First Posted: | June 23, 2010 Key Record Dates |
Results First Posted: | July 7, 2017 |
Last Update Posted: | July 7, 2017 |
Last Verified: | June 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Dexamethasone Anti-Inflammatory Agents Antiemetics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents |